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Recent studies have shown that mesenchymal stem cells 
(MSCs) are able to differentiate into multi-lineage cells such 
as adipocytes, chondroblasts, and osteoblasts. Amniotic 
membrane from whole placenta is a good source of stem cells 
in humans. This membrane can potentially be used for wound 
healing and corneal surface reconstruction. Moreover, it can 
be easily obtained after delivery and is usually discarded as 
classified waste. In the present study, we successfully isolated 
and characterized equine amniotic membrane-derived 
mesenchymal stem cells (eAM-MSCs) that were cultured and 
maintained in low glucose Dulbecco’s modified Eagle’s 
medium. The proliferation of eAM-MSCs was measured 
based on the cumulative population doubling level (CPDL). 
Immunophenotyping of eAM-MSCs by flow cytometry 
showed that the major population was of mesenchymal 
origin. To confirm differentiation potential, a multi-lineage 
differentiation assay was conducted. We found that under 
appropriate conditions, eAM-MSCs are capable of 
multi-lineage differentiation. Our results indicated that 
eAM-MSCs may be a good source of stem cells, making them 
potentially useful for veterinary regenerative medicine and 
cell-based therapy.
Keywords: amnion, amniotic membrane, equine, isolation, 
mesenchymal stem cells 
Introduction
The amniotic membrane, or amnion, is a layer of fetal 
membrane and one of the three placental layers [22]. 
During pregnancy, the placenta supports fetal development 
by supplying nutrients and oxygen to the uterine 
environment. Some reports have shown that the amniotic 
membrane can be used for healing wounds and corneal 
damage [22]. However, this membrane is usually treated as 
medical waste and discarded. 
Mesenchymal stem cells (MSCs), also known as 
multipotent stem cells or mesenchymal stromal cells, have 
unique characteristics such as a fibroblast-like morphology, 
expression of specific surface markers, and multipotent 
differentiation capacity [5,12]. Human MSCs can be isolated 
from various tissues including bone marrow, adipose tissue, 
umbilical cord blood, Wharton’s jelly, amniotic fluid, and 
placenta [2,8,10,13,16,18]. Additionally, many groups have 
isolated and characterized MSCs recovered from human 
amniotic membranes [5,15,17].
In equines, several reports have demonstrated that 
isolation and characterization of stem cells could be 
possible using equine-specific tissues such as bone 
marrow, umbilical cord blood, and adipose tissue [1,3,11]. 
Some studies examining transplantation with equine stem 
cells for therapeutic purposes in various experiment 
models of articular defect, tendinitis, and osteoarthritis 
have also been conducted [11,19,24,27]. However, it is 
accompanied methodologically surgical and invasive 
procedure to harvest stem cell source from bone marrow 
and adipose tissue [1,3], which method could cause 
suffering from animals. Umbilical cord blood can serve as 
a source of stem cells without the need for painful 
152    Min-Soo Seo et al.
harvesting methodologies. Nevertheless, studies of stem 
cells from umbilical cord blood are inadequate compared 
to ones evaluating stem cells from bone marrow and 
adipose tissue [4]. Similarly, amniotic membrane could 
also serve as a source of stem cells that are easily obtained 
on a large scale with minimal pain and suffering. 
In the present study, we successfully isolated and 
characterized equine amniotic membrane-derived MSCs 
(eAM-MSCs), and showed that these cells are capable of 
self-renewal and multi-lineage differentiation. Additionally, 
the cells proliferated vigorously and displayed a similar 
morphology to that typical of human MSCs. Therefore, we 
suggest that eAM may be a useful source of stem cells for 
veterinary cell-based therapy and regenerative medicine.
Materials and Methods
Amniotic membrane collection
All tissues were obtained via normal delivery without the 
use of any invasive methodologies. We used amniotic 
membranes that are normally discarded after delivery. The 
amnion samples were provided free of charge for the 
purposes of our study. The isolated membranes were only 
used for stem cell isolation and characterization. All safety 
compliances were strictly observed and the study adhered 
to the Policy and Regulation for Care and Use of 
Laboratory Animals (Institute of Laboratory Animal 
Resources, Seoul National University, Korea). 
All placental samples (n = 4) were obtained after 
parturition from Thoroughbred mares at a private horse 
farm in Korea. To prevent contamination and damage to 
the tissues, all samples were collected immediately after 
parturition using sterilized surgical equipment. The 
collected placenta samples were stored at 4oC and 
transported to the laboratory as quickly as possible. The 
amniotic membranes were mechanically peeled away from 
the allantois.
Cell isolation and primary culturing 
Cell isolation and culturing were performed as previously 
described with some modifications [5,21]. In brief, the 
collected amniotic membranes were washed with normal 
saline (0.9%) three∼four times under sterile conditions to 
remove debris and blood. To detach and remove the 
epithelial layer from the amniotic membranes, the 
membranes were treated with 0.05% trypsin for 1 h at 
37oC. After trypsinization, the membranes were washed 
with normal saline (0.9%) three∼four times. After 
washing, the amniotic membrane was minced with a 
surgical blade and scissors. The minced tissue was digested 
at 37oC for approximately 3∼4 h with collagenase type I (2 
mg/mL; Worthington Biochemical, USA). The digested 
samples were washed in phosphate-buffered saline (PBS; 
Corning, USA) and centrifuged at 350 × g for 5 min. The 
cell pellet was resuspended in basal culture medium 
composed of low glucose Dulbecco’s modified Eagle’s 
medium (LG-DMEM; Invitrogen, USA) containing 10% 
fetal bovine serum (FBS; Invitrogen, USA). The cells were 
cultured in a humidified atmosphere with 5% CO2. The 
basal culture medium was changed three times a week and 
passaged after reaching 80∼90% confluency. 
Cumulative population doubling level (CPDL) 
analysis
A cell proliferation assay was performed as previously 
described with some modifications [20]. Estimated growth 
efficiency and proliferation potential of the eAM-MSCs 
were determined based on the total CPDL using the 
formula CPDL = ln (Nf / Ni) ln2, where Ni is the initial 
number of cells seeded, Nf is the final number of harvested 
cells, and ln is the natural log. Cells (5 × 104) were plated 
in triplicate on a 6-well culture plate (Nalge Nunc 
International, USA) and subcultured for 5∼7 days. The 
cells were then counted and 5 × 104 cells were re-plated. To 
determine the CPDL, the population doubling for each 
passage was calculated and then added to the population 
doubling levels of the previous passages. 
Karyotype analysis
To detect any chromosomal abnormalities in the 
eAM-MSCs, a karyotype analysis was conducted followed 
by a standard Q-band analysis at passage 5. Briefly, mitosis 
was inhibited in eAM-MSCs with 0.1 μg/mL colchicine 
(Sigma) for 20 min. The cells were then suspended in a 
hypotonic solution (0.075M KCl) and incubated for 20 min 
at 37oC. Next, the cells were pelleted at 1,000 rpm for 10 
min and fixed by washing three times in methanol : glacial 
acetic acid (3 : 1). Chromosome spreads were obtained by 
pipetting the cell suspension onto clean glass slides and 
air-dried. Metaphases were captured with a CCD camera 
(Olympus, Japan), the chromosomes were counted, and 
banding patterns were analyzed. 
Flow cytometry 
Cells were stained for flow cytometry with specific 
antibodies following the supplier’s protocol (BD 
Biosciences, USA). In brief, cultured eAM-MSCs were 
washed twice in PBS and harvested using 0.25% 
trypsin/EDTA. The cells were then washed with PBS and 
divided into groups for antibody staining. Each aliquot 
contained approximately 1 × 105 cells. The following 
antibodies were used to detect cell surface antigens: mouse 
anti-human CD19, mouse anti-human CD20, mouse 
anti-human CD28, mouse anti-human CD31, mouse 
anti-human CD34, mouse anti-human CD38, mouse 
anti-human CD41a, mouse anti-human CD44, mouse 
anti-human CD62L, mouse anti-human CD62P, mouse 
anti-human CD90, mouse anti-human CD200 (BD 
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Biosciences, USA), and mouse anti-human CD105 (AbD 
Serotec, USA). All antibodies were conjugated with 
fluorescein isothiocyanate or phycoerythrin. The cells 
were stained for 30 min at 4oC. After incubation, the cells 
were washed with PBS and re-suspended in 500 µL of 
PBS. Analysis was performed with a FACS Calibur flow 
cytometer (BD Biosciences, USA) and Cell Quest Pro 
software (BD Biosciences, USA).
Osteogenic differentiation assay
To test for osteogenic capacity, eAM-MSCs were treated 
with osteogenic differentiation medium containing 
ascorbic acid 2-phosphate (50 μM), dexamethasone (100 
nM), β-glycerophosphate (10 mM; Sigma-Aldrich, USA), 
and 10% FBS in LG-DMEM. The cells (1 × 105) were 
plated in triplicate on 6-well plates. When the cells were 80∼90% confluent, the culture medium was changed to the 
osteogenic differentiation medium and the cells were 
incubated for 3 weeks. The differentiation medium was 
changed twice weekly. After differentiation, the cells were 
stained with Alizarin Red S and von Kossa reagent to 
detect calcium deposition. For Alizarin Red S staining, the 
cells were washed with PBS and fixed with ice-cold 70% 
ethanol for 1 h at 4oC. Next, the cells were rinsed three to 
four times with distilled water and stained with Alizarin 
Red S (40 mM, pH 4.2; Sigma-Aldrich, USA) for 10 min at 
room temperature. To remove excess dye, the cells were 
rinsed with distilled water. Cells stained with Alizarin Red 
S were solubilized in cetylpyridinium chloride (100 mM; 
Sigma-Aldrich, USA) for 1 h. Absorbance of the 
solubilized cells was measured at 570 nm using a 
spectrophotometer [20]. For von Kossa staining, the cells 
were stained with 5% silver nitrate for 30 to 60 min while 
exposed to ultraviolet light, incubated with 5% sodium 
thiosulfate for 2 to 3 min, and then counterstained with 
Nuclear Red Stain for 5 min. 
Adipogenic differentiation analysis
To test for adipogenic differentiation capacity, eAM-MSCs 
were treated with adipogenic differentiation medium 
composed of dexamethasone (1 μM), indomethacin (60 
μM), 3-isobutyl-1-metylxanthine (500 μM), insulin (5 
μg/mL; Sigma-Aldrich, USA), and 10% FBS in LG-DMEM 
for 3 weeks after reaching 80∼90% confluency. The 
medium was replaced twice weekly. After differentiation, 
Oil Red O staining was conducted to confirm the formation 
of lipid inclusions. The cells were fixed in 10% formalin 
for at least 1 h and rinsed with 60% isopropanol prior to 
incubation in freshly diluted Oil Red O for 10 min. Stains 
were solubilized with 100% isopropanol, and the resulting 
absorbance was measured at 500 nm using a 
spectrophotometer [20].
Chondrogenic differentiation assay
To test for chondrogenic capacity, eAM-MSCs were 
treated with chondrogenic differentiation medium. The 
cells (5 × 105) were transferred to a 15-mL polypropylene 
tube and pelleted. The pellets were cultured in 1 mL of 
chondrogenic differentiation medium (Lonza, 
Switzerland) for 3 weeks. The medium was changed three 
times weekly. After differentiation, the pellets were 
embedded in paraffin and 3-µm sections were cut. To 
detect chondrogenesis, the sections were stained with 
toluidine blue and Alcian blue-PAS following standard 
protocols [20]. In brief, a 3-µm cell pellet section mounted 
on a slide was deparaffinized and hydrated with distilled 
water. For toluidine blue staining, the slide was immersed 
in a toluidine blue working solution for 1 min. Excess 
unbound stain was removed by several washes with 
distilled water. The slide was quickly dehydrated with 
sequential washes of 95% and absolute alcohol. For Alcian 
blue-PAS staining, the slide was stained with Alcian blue 
(pH 2.5), 0.5% periodic acid, and Schiff’s reagent. The 
slide was cleared with xylene and covered with Canada 
balsam and a coverslip. 
Statistical analysis 
The data were analyzed by Student’s t-test using Excel 
software and expressed as the mean ± standard error (SE). 
Statistical significant data were indicated by asterisk (***p ＜ 0.001, **p ＜ 0.01). 
Results
eAM-MSC isolation and culturing
Placenta tissues were collected from mares after 
parturition. The collected tissues were quickly transported 
to the laboratory to prevent possible contamination from 
the dusty environment of the stall where the horses were 
housed. Under sterile condition, we peeled the amniotic 
membrane away from the placenta tissue using surgical 
instruments (Fig. 1A). We isolated and cultured 
eAM-MSCs with a fibroblast-like and spindle morphology 
typical of MSCs, and that adhered to the plastic culture dish 
surface (Figs. 1B and C). To measure the proliferation 
potential of the isolated eAM-MSCs, we calculated the 
CPDL. eAM-MSCs (5 × 104 cells/well) were seeded in a 
6-well culture plate and subcultured 5∼7 days later. The 
procedure was repeated until passage 14 to measuring the 
CPDL. The stable increasing graph of cell growth was 
observed (Fig. 1D). The cells were also confirmed to have 
a normal karyotype with 64 chromosomes (Fig. 1E). 
Immunophenotypic characterization using flow 
cytometry
We conducted flow cytometric analysis of the 
eAM-MSCs at passage 5 and monitored the expression of 
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Fig. 1. Primary culturing of equine amniotic membrane-derived mesenchymal stem cells (eAM-MSCs) and determination of the 
cumulative population doubling level (CPDL). (A) Harvesting of eAM tissue. (B and C) Phase contrast images of eAM-MSCs. The 
cells were cultured in low glucose Dulbecco’s modified Eagle’s medium (LG-DMEM) with 10% FBS. The cells had a spindle 
morphology with a fibroblast-like structure similar to that of human MSCs. Scale bars = 50 μm. (D) Cell growth curve of the 
eAM-MSCs. The CPDL was measured from passage 3 to passage 14, and evaluated as described in the Materials and Methods section.
Cells grew consistently until passage 14. (E) Karyotype of eAM-MSCs at passage5 showing a euploid number of chromosomes. 
13 CD markers (CD19, CD20, CD28, CD31, CD34, 
CD38, CD41a, CD44, CD62L, CD62P, CD90, CD105, 
and CD200) to determine whether the cells displayed an 
MSC phenotype (Fig. 2). The eAM-MSCs expressed 
CD44, CD90 and CD105. CD90, also known as Thy-1, is 
a marker for various types of stem cells including hepatic 
stem cells, keratinocyte stem cells, endometrial stem cells, 
and MSCs. CD105, which is also called SH2, is a 
well-known MSC marker. Other markers such as those 
expressed by immune cells (CD19, CD20, CD28, CD38, 
CD62L and CD200), endothelial cells (CD31 and CD62P), 
hematopoietic cells (CD34), and platelets (CD41a) were 
not found. 
Osteogenesis
Calcium mineralization of eAM-MSCs treated with 
osteogenic induction medium was detected by Alizarin 
Red S or von Kossa staining, and indicated osteogenesis. 
Cells grown in basal culture medium alone were used as a 
negative control. After osteogenic differentiation, positive 
and strong Alizarin Red S and von Kossa staining was 
detected (Figs. 3C, D, G, and H). Under basal culture 
conditions, the cells were negative for Alizarin Red S and 
von Kossa staining (Figs. 3A, B, E, and F). For 
quantification, cells stained with Alizarin Red S were 
solubilized with 100 mM cetylpyridinium chloride and the 
absorbance was measured. Compared to the negative 
control, absorbance for the differentiated cells was 
approximately 15-fold greater (Fig. 3I). 
Adipogenesis
To confirm the ability of eAM-MSCs to undergo 
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Fig. 2. Flow cytometry analysis of eAM-MSCs. The analysis was performed at passage 5. Values show the signal intensity of the 
indicated antigen. 
adipogenesis, the cells were treated with adipogenic 
induction medium that was changed every 3 days for 3 
weeks. After differentiation, the cells were stained with Oil 
Red O to detect the formation of lipid inclusions. Under 
differentiation conditions, lipid droplets stained with Oil 
Red O were observed (Figs. 4C and D). Black arrows in Fig. 
4D indicate the stained lipid droplets. No Oil Red O stating 
was observed in cells grown under basal culture medium 
that were used as a negative control (Figs 4A and B). For 
quantification, the cells were solubilized with 100% 
isopropanol and the absorbance was measured. Absorbance 
for the differentiated cells was approximately five-times 
greater than that for the negative control (Fig. 4E).
Chondrogenesis
To confirm the chondrogenesis potential of the 
eAM-MSCs, the cells were seeded into 15-mL 
polypropylene tubes and pelleted. The pellets were 
incubated at 37oC in a 5% CO2 incubator with 
chondrogenic induction medium that was changed every 3 
days for 3 weeks. After differentiation, we observed the 
formation of pellets in the bottom of the polypropylene 
tube. The pellets formed an ovoid and opaque structure 
(Figs. 5A and B). The black arrow indicates the pellet 
formation (Fig. 5A). Pellet formation was not observed for 
cells grown under control conditions. The control cells 
dispersed when the medium was changed, indicating that 
chondrogenesis had not occurred with the basal culture 
medium. The pellet was positive for staining with toluidine 
blue (Fig. 5C) and Alcian blue-PAS (Fig. 5D). 
Discussion
The placenta, which is of both fetal and maternal origin, is 
round and has numerous blood vessels, grows throughout 
pregnancy, and consist of three membrane layers. 
Functions of the placenta include transporting nutrients 
from the mother to the fetus, allowing waste elimination, 
and facilitating gas exchange. These functions are essential 
for fetal survival and development [28]. The amnion is the 
innermost of the two fetal membranes. It encloses the fetus, 
allowing it to move freely and providing protection from 
the external environment. The amniotic membrane has a 
thin, nonvascular structure with two layers: an epithelial 
monolayer and stromal layer [28]. 
After parturition, the placenta is classified as medical 
waste and usually discarded. There are, however, clinical 
studies showing that the amniotic membrane can 
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Fig. 3. Osteogenic differentiation of the eAM-MSCs. Negative control cells (A, B, E, and F) were grown in LG-DMEM with 10% FBS. 
No Alizarin Red S or von Kossa staining was observed. The cells (C, D, G and H) were also grown in osteogenic induction medium. 
The differentiated cells showed strong Alizarin Red S (C and D) and von Kossa (G and H) staining. Scale bars = 50 μm. For 
quantification, Alizarin Red S-stained cells were solubilized with 100 mM cetylpyridinium chloride and the absorbance was measured
spectrophotometrically at 570 nm for 0.5 seconds (I). Compared to the negative control, absorbance for the differentiated cells was 
approximately 15-fold greater. (A∼H) Alizarin Red S and von Kossa staining after 3 weeks of osteogenic induction or culturing under
control conditions. All analyses were performed in triplicate and the mean ± standard deviation (SD) was plotted (***p ＜ 0.001).
potentially be used to promote wound healing and corneal 
reconstruction [9,25]. Additionally, isolation and 
characterization of human MSCs from the amniotic 
membrane and whole placenta have also been reported 
[22]. These stem cells have tri-lineage differentiation and 
self-renewal capabilities, which are characteristic MSC 
features. MSCs have many advantages for use in cell-based 
therapy including immune privilege, an absence of 
associated ethical issues, and no requirement of invasive 
procedures for harvesting the amnion. Recently, 
equine-derived stem cells were isolated and their potential 
use in cell-based therapy was examined [7,19,24,27]. 
However, these investigations have been confined to 
limited stem cell sources such as equine adipose tissue, 
umbilical cord blood, and bone marrow [1,3,11]. Therefore, 
a greater diversity of stem cell sources is required.
In the present study, we successfully isolated and 
characterized MSCs from eAM. The collected amniotic 
membrane was enzymatically digested to recover the cells. 
After digestion, the eAM-MSCs were seeded in basal 
culture medium until passage 14. Using this procedure, we 
obtained cells from four equine amniotic tissue samples. 
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Fig. 4. Adipogenic differentiation of the eAM-MSCs. Negative 
control cells (A and B) were grown in LG-DMEM with 10% 
FBS. No Oil Red O staining was observed in the control cells. (C
and D) Cells were also grown in adipogenic induction medium. 
Lipid droplets within the differentiated cells were strongly 
stained with Oil Red O. Black arrows indicate the fat droplets 
stained red. Scale bars = 50 µm. For quantification, stained cells 
were solubilized with 100% isopropanol, and absorbance was 
measured spectrophotometrically at 500 nm for 0.5 seconds (E). 
Compared to the negative control, absorbance of the 
differentiated cells was approximately 5-fold greater. (A∼D) Oil
Red O staining after 3 weeks of adipogenic induction. All 
analyses were performed in triplicate and the mean ± SD was 
plotted (**p ＜ 0.01).
Fig. 5. Chondrogenic differentiation of the eAM-MSCs. After 3 
weeks of chondrogenic induction, pellet formation was observed. 
(A) Formation of chondrogenic pellets occurred at the bottom of
a 15-mL polypropylene tube. The black arrow indicates a pellet. 
(B) Image of an oval-shaped chondrogenic pellet. (C) Toluidine 
blue and (D) Alcian blue-PAS staining of the chondrogenic 
pellets. The pellets were embedded in paraffin and cut into 3-µm
sections that were mounted on slides. The sections were stained 
with toluidine blue and Alcian blue-PAS. A typical cartilaginous
tissue phenotype was observed. Scale bars = 100 μm.
The rate of success was 100%, and all isolated cells (from 
all four samples) showed similar morphologies. The cells 
were subcultured on the surface of plastic culture dishes. A 
single cell line was randomly selected. All experiments 
including CDPL determination, flow cytometric analysis, 
and differentiation studies were conducted using only the 
selected cell line (in triplicate).
A consistent level of cell proliferation is a distinct 
characteristic of stem cells. These cells have a self-renewal 
ability related to continuous and steady proliferation. Our 
results demonstrated that the isolated eAM-MSCs are 
capable of self-renewal, a typical feature of mesenchymal 
cells. Furthermore, the cells were fibroblast-like, adhered 
to the plastic culture dish surface, and possessed a normal 
karyotype. Due to their robust proliferation, the 
eAM-MSC may be sufficient for in vivo applications. 
Immunophenotype characterization indicated that the 
eAM-MSCs were positive for MSCs markers such as CD44 
(98.98%), CD90 (100%), and CD105 (100%). CD44 is a 
cell-surface glycoprotein that plays a role in MSC 
migration [23]. MSCs display a distinctive pattern of cell 
surface antigens such as CD44, CD90, and CD105. 
Antigens that are not typically found on MSCs include 
CD11b, CD14, CD19, CD79a, CD34, CD45, and HLA-DR 
[6]. Our results demonstrated that eAM-MSCs have an 
immunophenotype similar to that of a typical MSC. Since 
there are no equine-specific antibodies appropriate for flow 
cytometry, we used human host antibodies that have 
cross-reactivity among different species [20]. Our previous 
study showed a similarity between Equus caballus and 
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Homo sapiens CD markers by comparing amino acid 
sequences. All CD markers used for the present study have 
amino acid sequences suitable for cross-reactivity (56∼
84%). For MSC characterization using flow cytometry, it is 
essential to confirm the expression levels of CD45 and 
CD73. While, identity of CD45 and CD73 were not 
investigated since reference sequence of Equus caballus 
did not exist [20]. A previous study also examined equine 
surface antigen expression using anti-rat antibodies based 
on the same principle of interspecies cross-reactivity [3]. 
Although these data demonstrated the high degree of 
similarity between Equus caballus and Homo sapiens CD 
markers, more equine-specific antibodies for flow 
cytometry should be identified to confirm the identity of 
equine-derived stem cells.
In addition, we demonstrated the multipotent 
differentiation capability of eAM-MSCs. We found that 
eAM-MSCs differentiated into osteocytes, adipocytes, and 
chondrocytes using specific culture media. eAM-MSCs 
grown under osteogenic differentiation conditions 
acquired calcium deposits identified with Alizarin Red S 
and von Kossa staining. Calcium accumulation was not 
observed in cells cultured under control conditions. In the 
adipogenic differentiation study, lipid droplets were 
observed in the cells after 3 weeks of differentiation. To 
confirm adipogenic differentiation, we performed Oil Red 
O staining. Differentiated cells were positive for Oil Red O 
staining although only a few cells were stained and 
contained fat droplets. We tried to increase the adipogenic 
efficiency with various methods but could not observe any 
difference (data not shown). It might be that eAM-MSCS 
differentiation favored the osteogenic axis rather than the 
adipogenic axis. Findings similar to the ones from our 
study were reported in animal tissue-derived stem cells 
[20,26], and it could be that osteogenesis and adipogenesis 
are achieved through competing pathways [14]. In the 
chondrogenic differentiation study, cells that were cultured 
in chondrogenic differentiation medium aggregated and 
formed pellets unlike cells that were grown in the control 
medium. The differentiated cells were also positive for 
toluidine blue and Alcian blue-PAS staining. 
For clinical cell-based therapies, large numbers of stem 
cells from diverse sources are required. In large animals 
such as horses, two major barriers for clinical cell therapy 
are the limited number of stem cell sources and difficulties 
in identifying stem cells. In the current study, we isolated 
stem cells from eAM. These cells were found to have an 
immunophenotype characteristic of MSCs and are capable 
of self-renewal. Moreover, the rate of eAM-MSC 
proliferation was stable until passage 14. Taken together, 
these findings suggest that eAM-MSCs are a potential 
source of stem cells and could be useful for regenerative 
medicine in horses. 
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